LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model

Mostrar otras versiones (2)

No treatments exist to slow or halt Parkinson’s disease (PD) progression; however, inhibition of leucine-rich repeat kinase 2 (LRRK2) activity represents one of the most promising therapeutic strategies. Genetic ablation and pharmacological LRRK2 inhibition have demonstrated promise in blocking α-sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Hien Tran, John, Neena, Delic, Vedad, Ikeda-Lee, Karli, Kim, Aneeza, Weihofen, Andreas, Swayze, Eric E., Kordasiewicz, Holly B., West, Andrew B., Volpicelli-Daley, Laura A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573879/
https://www.ncbi.nlm.nih.gov/pubmed/28918051
http://dx.doi.org/10.1016/j.omtn.2017.08.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573879/
https://www.ncbi.nlm.nih.gov/pubmed/28918051
http://dx.doi.org/10.1016/j.omtn.2017.08.002

Ejemplares similares